ANTITUMORAL EFFECTS OF R75251 ON THE GROWTH OF TRANSPLANTABLE R3327 PROSTATIC ADENOCARCINOMA IN RATS

The antitumoral activity of a novel imidazole derivative, R 75251, has been studied in the androgen‐dependent R3327G Dunning prostate adenocarcinoma grafted subcutaneously in syngeneic rats. Dietary application resulting approximately in dose levels of 80, 120, and 160 mg/kg reduced tumor weight by 66, 81, and 79%, respectively. This effect was not significantly different from that measured after castration (‐ 82%). In intact animals, however, serum testosterone levels were almost not affected by R 75 251 treatment while LH levels rose two‐ to threefold. In castrated rats a tenfold increase in LH was observed. Moreover, prostate and seminal vesicles weights decreased much less after R 75 251 treatment than after castration. In castrated animals, treatment with R 75 251 induced a slight, non‐significant reduction in tumor weight (‐ 36%) compared with castration alone. In castrated animals, tumor growth was restored by exogenous administration of testosterone. In such animals R 75 251 also significantly reduced tumor weight by 57%. Similar results were obtained with Dunning R3327G prostate adenocarcinoma grafted beneath the renal capsule in male syngeneic rats receiving twice daily orally by gavage a dose of 80 mg/kg of R 75 251. These data suggest that R 75 251 exerts an antitumoral effect independent of its inhibition of androgen biosynthesis. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company